

2nd CRIG Industrial Partnering Event

25th October 2019 - AuditoRium 4, Sint-Denijslaan 485, Ghent (Belgium)

Preliminary program:

8.00-9.00 Breakfast sessions – Discussion tables on developments and innovation in

- 1. Immuno-oncology (moderator: Karim Vermaelen, UZGent-CRIG)
- 2. Clinical trials
- 3. Al and precision medicine (moderator: Ingrid Mas, Inovigate)
- 4. Topic of choice (upon registration)
- 9:00-9:10 Welcome Prof. Jo Vandesompele, UGent, CRIG Chairman
- 9.10-10:00 Plenary talk Dr. David Gilham, Celyad (title to be confirmed)

10:00-10:50 Parallel sessions 1

Session 1A "Innovations in cancer therapy: immuno-oncology" (moderated by Hetty

Helsmoortel, molecular biologist & science communicator)

- 'CAR-T trials at UZ Gent: being a privileged partner of the industry in a novel field' Prof. Tessa Kerre (U(Z)Gent, CRIG)
- 'Challenges and hurdles in CAR-T treatment of children' Prof. Barbara De Moerloose (U(Z)Gent, CRIG)
- 'GMP facility: on site production of immunotherapeutics at UZ Gent' Prof. Bart Vandekerckhove (U(Z)Gent, CRIG)
- 'The CliniMACS Prodigy as platform for centralized CAR-T cell production' Jordy Blaauwendraad (Miltenyi Biotec)
- Pitch by Janssen Pharmaceutica (*title to be confirmed*) Dr. Janine Arts
- 'Quality by Design to accelerate T-cell based process development' Gisèle Deblandre (MaSTherCell)

Session 1B "Innovations in cancer therapy: RNA based therapies, antibody/peptide therapies and cancer vaccines"

- 'NESPR and pipeline/screening platform for novel lncRNA abled therapies' Prof. Pieter Mestdagh (UGent, CRIG)
- 'Repurposing cationic amphiphiles for improved cellular delivery of RNA therapeutics' Prof. Koen Raemdonck (UGent, CRIG)
- 'Applications of vaccines adjuvant in immuno-oncology'
- Dr. Jean -François Toussaint (GlaxoSmithKline)
- 'mRNA Galsomes: making mRNA vaccines more effective and controlled' Dr. Ine Lentacker (UGent, CRIG)



- 1 CRIG pitch
- 1 company pitch

10:50-11:10 **Coffee break & sponsor booths**

11:10-12:00 Parallel sessions 2:

<u>Session 2A "Innovations in cancer therapy: immuno-oncology"</u> (moderated by Hetty Helsmoortel – UGent, CRIG)

• 'Taking dendritic cells to medicine: the MIDRIX platform for vaccination in lung cancer and beyond'

Prof. Karim Vermaelen (U(Z)Gent, CRIG)

- Pitch by AstraZeneca (title & speaker to be confirmed)
- 'Drug targeting to lymphoid tissue'
 - Prof. Bruno De Geest (UGent, CRIG)
- 'The BiTE technology' Amgen (speaker to be confirmed)
- Pitch by CRIG on NK therapy (title to be confirmed) Prof. Georges Leclercq (UGent, CRIG)
- 'Combination of immunotherapy and radiotherapy in clinical trials' Prof. Piet Ost (U(Z)Gent, CRIG)

Session 2B "Cancer modelling"

- 'Dog models of naturally occurring cancer' Prof. Hilde de Rooster (UGent, CRIG)
- 'Spontaneous microbiota-driven metastatic CRC mouse model' Prof. Lars Vereecke (VIB-UGent, CRIG)
- 'Selecting the right leukemia therapy' Prof. Steven Goossens (VIB-UGent, CRIG)
- 'The xenopus platform' Prof. Kris Vleminckx (UGent, CRIG)
- 1 CRIG pitch
- 1 CRIG/company pitch
- 12:00-12:50 **Speed dating round** (moderated by Dr. Hetty Helsmoortel (molecular biologist & science communicator, CRIG)
- 12.50-13.50 Lunch, partnering discussions & sponsor booths
- 13.50-14.40 Plenary talk 'Digital-enabled Innovations in Cancer Care' Prof. Hans Hofstraat, Philips Research

14:40-15:30 Parallel sessions 3

<u>Session 3A "Precision oncology"</u> (moderated by Hetty Helsmoortel – UGent, CRIG)

 'Cancer therapeutics and barrier dysfunction/dysbiosis' Prof. An Hendrix (UGent, CRIG)



• 'Targeted proximity ligation assays & NGS for robust detection of structural variation in fragmented FFPE samples'

Dr. H. Feitsma (Cergentis)

- 'OncoLize Treating tumors from the Inside' Dr. Mike de Leeuw (OncoLize)
- 2 CRIG pitches
- 1 company pitch

Session 3B "New players in the Belgian ecosystem and spinoff projects in oncology" (moderated by dr. Daisy Flamez - UGent, CRIG)

- 'Cancer-T in motion, a novel platform for informing patients through digital tools' Prof. Tessa Kerre (U(Z)Gent, CRIG)
- 'CRIG as beta user: Trince'
 - Dr. Stephan Stremersch, Prof. Kevin Braeckmans (UGent, CRIG)
- 'OhmX.Bio and NXTGNT'
 - Prof. Gerben Menschaert
- 'Gulliver BioMed'
 - Prof. Jan Gettemans
- 2 pitches

15:30-15:50 Coffee break & sponsor booths

15:50-16:50 Parallel sessions 4:

<u>Session 4A: "Platforms and technologies in (non-invasive) diagnostics</u>" (moderated by dr. Hetty Helsmoortel – UGent, CRIG)

- 'New alphabodies platform validation' Prof. Pieter Van Vlierberghe (UGent, CRIG)
- Pitch by Stilla Technologies (speaker & title to be confirmed)
- 'High throughput immunoprofiling for cancer diagnostics' Christof Neuman (IPDx)
- 'Methylation cell free DNA' Prof. K. De Preter (U(Z)Gent, CRIG)
- 'Molecular profiling of solid tumors and hematological malignancies using targeted sequencing'
 - J. Van der Meulen (U(Z)Gent, CRIG)
- 'Cell by Design[®] (CbD), a cloud-based software platform that facilitates scalable, cost effective and sustainable ATMP process development'
 - Dominiek Rossillion (QBD) & Evan Claes (Antleron)
- 1 CRIG pitch

Session 4B "AI, digital health, Big Data" (moderated by dr. Ingrid Maes - Inovigate)

- 'Deep Learning for metastasis detection in lymph nodes, and others' Nicolas Deruytter (ML6)
- 'Biocartis Idylla[™] the art of intelligence inside a box' Dr. Bram De Craene (Biocartis)



- 'Big single-cell data science for cancer application' • Prof. Yvan Saeys (VIB-UGent, CRIG)
- Pitch by CRIG (title to be confirmed) Dr. Lieve Brochez (UZGent, CRIG)
- 'The Universal Digital Health Platform initiative, a patient data-centric digital health ٠ solution connecting industry, HCPs and patients to deliver personalised and cost-efficient outcomes'
 - Dr. Ingrid Maes (Inovigate)
- 1 CRIG pitch •
- 1 company pitch •
- 16.50-17:00 Summary & closing remarks
- 17.00-18.00 Networking reception & partnering discussions

Thanks to our sponsors!

Gold sponsors













Silver sponsors















